309 LuxS, MPP, ThrRS/AlaRS common domain
Ligands and drugs
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.
The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.
| Superclass | Proteins | Expected | 0.25×observed / expected4× | Ratio | Significance |
|---|---|---|---|---|---|
| Lipids and lipid-like molecules | 12 | 5.3 | 2.28× | q = 9.8e-3 | |
| Homogeneous metal compounds | 35 | 23.2 | 1.51× | q = 1.9e-3 | |
| Organic acids and derivatives | 9 | 7.3 | 1.23× | q = 0.63 | |
| Homogeneous non-metal compounds | 5 | 10.2 | 0.49× | q = 0.12 | |
| Organoheterocyclic compounds | 2 | 7.3 | 0.28× | q = 0.05 | |
| Organic oxygen compounds | 2 | 9.4 | 0.21× | q = 7.2e-3 | |
| Nucleosides, nucleotides, and analogues | 2 | 13.1 | 0.15× | q = 2.0e-4 | |
| Benzenoids | 3 | 3.5 | 0.87× | not tested |
Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB03429 | CDL | Tetrastearoyl cardiolipin | 78 |
| DB04327 | PEE | Phosphatidylethanolamine | 41 |
| DB09114 | PCF | Colfosceril palmitate | 31 |
| DB02686 | UMQ | Undecyl-Beta-D-Maltopyranoside | 14 |
| DB01728 | PEF | 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine | 12 |
| DB00134 | MET | Methionine | 8 |
| DB00161 | VAL | Valine | 4 |
| DB00626 | — | — | 4 |
| DB04141 | — | 2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol | 4 |
| DB04799 | — | 6-Hydroxy-5-undecyl-4,7-benzothiazoledione | 4 |
| DB07401 | — | Azoxystrobin | 4 |
| DB07763 | — | (5S)-3-ANILINO-5-(2,4-DIFLUOROPHENYL)-5-METHYL-1,3-OXAZOLIDINE-2,4-DIONE | 4 |
| DB07778 | — | (S)-famoxadone | 4 |
| DB08330 | — | METHYL (2Z)-3-METHOXY-2-{2-[(E)-2-PHENYLVINYL]PHENYL}ACRYLATE | 4 |
| DB08453 | — | 2-Nonyl-4-quinolinol 1-oxide | 4 |
| DB08690 | — | Ubiquinone Q2 | 4 |
| DB00133 | SER | Serine | 3 |
| DB00171 | ATP | ATP | 3 |
| DB00156 | — | Threonine | 2 |
| DB00160 | — | Alanine | 2 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| ZNmetal | ZINC ION | 205 |
| CDL | CARDIOLIPIN | 147 |
| PC1 | 1,2-DIACYL-SN-GLYCERO-3-PHOSPHOCHOLINE | 94 |
| PEE | 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine | 52 |
| PTY | PHOSPHATIDYLETHANOLAMINE | 38 |
| XP4 | 1,2-DIMYRISTOYL-SN-GLYCERO-3-PHOSPHATE | 36 |
| 3PE | 1,2-Distearoyl-sn-glycerophosphoethanolamine | 27 |
| PLX | (9R,11S)-9-({[(1S)-1-HYDROXYHEXADECYL]OXY}METHYL)-2,2-DIMETHYL-5,7,10-TRIOXA-2LAMBDA~5~-AZA-6LAMBDA~5~-PHOSPHAOCTACOSANE-6,6,11-TRIOL | 23 |
| PCF | 1,2-DIACYL-SN-GLYCERO-3-PHOSHOCHOLINE | 21 |
| UNL | Unknown ligand | 20 |
| 6PH | (1R)-2-(phosphonooxy)-1-[(tridecanoyloxy)methyl]ethyl pentadecanoate | 17 |
| PEF | DI-PALMITOYL-3-SN-PHOSPHATIDYLETHANOLAMINE | 14 |
| CL | CHLORIDE ION | 13 |
| I41 | 2-[[2-[[(2S)-3-(3H-IMIDAZOL-4-YL)-1-METHOXY-1-OXO-PROPAN-2-YL]AMINO]-2-OXO-ETHYL]-(PHENYLMETHYL)AMINO]ETHANOIC ACID | 11 |
| 6PE | 1,2-DIHEXANOYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE | 10 |
| PX4 | 1,2-DIMYRISTOYL-SN-GLYCERO-3-PHOSPHOCHOLINE | 9 |
| J22 | {(8R,9S,10S)-9-(2',3'-dimethyl[1,1'-biphenyl]-4-yl)-6-[(1-methyl-1H-imidazol-2-yl)sulfonyl]-1,6-diazabicyclo[6.2.0]decan-10-yl}methanol | 8 |
| MET | METHIONINE | 8 |
| UMQ | UNDECYL-MALTOSIDE | 7 |
| 2Q6 | methyl [(2S)-2-[4-({5-[4-({(2S)-2-[(3S)-3-amino-2-oxopiperidin-1-yl]-2-cyclohexylacetyl}amino)phenyl]pentyl}oxy)phenyl]-3-(quinolin-3-yl)propyl]carbamate | 6 |